RedHill Biopharma Receives Approval for Phase 2/3 COVID-19 Study in Russia

Clinical Trial Application approved in Russia for the Phase 2/3 study with opaganib in severe COVID-19 patients following recent approval in the UK and similar submission in Italy
--
The Phase 2/3 study aims to enroll 270 subjects in up to 40 clinical sites; enrollment planned to be initiated later......
. .
Veröffentlicht von: Finanzen.at - Nachrichten Ticker - Thursday, 16 July

Share |